Literature DB >> 24872394

Controlled human malaria infection.

Michele Spring1, Mark Polhemus1, Christian Ockenhouse1.   

Abstract

BACKGROUND: Since 1986, investigators at Walter Reed Army Institute of Research (WRAIR) have been using controlled human malaria challenge (CHMI) in malaria-naive adults in order to define the protective efficacy of a malaria vaccine and thus guide programmatic decisions on vaccine candidates. Adapting this model to the dengue field could provide similar evidential support for a vaccine or therapeutic product.
METHODS: After completing a vaccine regimen, volunteers are bitten by 5 malaria-infected female Anopheles mosquitoes in a controlled environment. Volunteers are then monitored daily for peripheral parasitemia in a hotel setting with 24-hour access to a nurse and physician. If a single verified parasite is detected, effective antimalarials are promptly administered.
RESULTS: The vast majority of the over 1000 volunteers having participated in CHMI clinical studies have done so at US military research centers. Numerous pre-erythrocytic and erythrocytic vaccine candidates have been evaluated safely and without any related serious adverse events using this model, including the soon-to-be licensed RTS,S malaria vaccine.
CONCLUSION: The lessons learned from over 25 years of experience in consistent, careful preparation and execution of the CHMI model at WRAIR can provide a foundation from which the dengue field can begin to develop a rigorous and safe "CHDI" model.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  clinical trial; efficacy; malaria; challenge; mosquito

Mesh:

Substances:

Year:  2014        PMID: 24872394     DOI: 10.1093/infdis/jiu063

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  34 in total

Review 1.  Malaria vaccine clinical trials: what's on the horizon.

Authors:  Alberto Moreno; Chester Joyner
Journal:  Curr Opin Immunol       Date:  2015-07-13       Impact factor: 7.486

Review 2.  Malaria medicines: a glass half full?

Authors:  Timothy N C Wells; Rob Hooft van Huijsduijnen; Wesley C Van Voorhis
Journal:  Nat Rev Drug Discov       Date:  2015-05-22       Impact factor: 84.694

Review 3.  Vaccinology in the era of high-throughput biology.

Authors:  Helder I Nakaya; Bali Pulendran
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-06-19       Impact factor: 6.237

4.  The Controlled Human Malaria Infection Experience at the University of Maryland.

Authors:  DeAnna J Friedman-Klabanoff; Matthew B Laurens; Andrea A Berry; Mark A Travassos; Matthew Adams; Kathy A Strauss; Biraj Shrestha; Myron M Levine; Robert Edelman; Kirsten E Lyke
Journal:  Am J Trop Med Hyg       Date:  2019-03       Impact factor: 2.345

Review 5.  An expanding toolkit for preclinical pre-erythrocytic malaria vaccine development: bridging traditional mouse malaria models and human trials.

Authors:  Ryan Wj Steel; Stefan Hi Kappe; Brandon K Sack
Journal:  Future Microbiol       Date:  2016-11-18       Impact factor: 3.165

6.  Mosquito Bite-Induced Controlled Human Malaria Infection with Plasmodium vivax or P. falciparum Generates Immune Responses to Homologous and Heterologous Preerythrocytic and Erythrocytic Antigens.

Authors:  Cysha E Hall; Lisa M Hagan; Elke Bergmann-Leitner; Donna M Tosh; Jason W Bennett; Jason A Regules; Ilin Chuang; Evelina Angov; Sheetij Dutta; Debasish Chattopadhyay; Anjali Yadava
Journal:  Infect Immun       Date:  2019-02-21       Impact factor: 3.441

7.  A Monoclonal Antibody for Malaria Prevention.

Authors:  Martin R Gaudinski; Nina M Berkowitz; Azza H Idris; Emily E Coates; LaSonji A Holman; Floreliz Mendoza; Ingelise J Gordon; Sarah H Plummer; Olga Trofymenko; Zonghui Hu; Andrezza Campos Chagas; Sarah O'Connell; Manjula Basappa; Naomi Douek; Sandeep R Narpala; Christopher R Barry; Alicia T Widge; Renunda Hicks; Seemal F Awan; Richard L Wu; Somia Hickman; Diane Wycuff; Judy A Stein; Christopher Case; Brian P Evans; Kevin Carlton; Jason G Gall; Sandra Vazquez; Britta Flach; Grace L Chen; Joseph R Francica; Barbara J Flynn; Neville K Kisalu; Edmund V Capparelli; Adrian McDermott; John R Mascola; Julie E Ledgerwood; Robert A Seder
Journal:  N Engl J Med       Date:  2021-08-11       Impact factor: 91.245

Review 8.  Mosquito Saliva: The Hope for a Universal Arbovirus Vaccine?

Authors:  Jessica E Manning; David M Morens; Shaden Kamhawi; Jesus G Valenzuela; Matthew Memoli
Journal:  J Infect Dis       Date:  2018-06-05       Impact factor: 5.226

9.  Investigating zoonotic infection barriers to ape Plasmodium parasites using faecal DNA analysis.

Authors:  Dorothy E Loy; Meagan A Rubel; Alexa N Avitto; Weimin Liu; Yingying Li; Gerald H Learn; Alessia Ranciaro; Eric Mbunwe; Charles Fokunang; Alfred K Njamnshi; Paul M Sharp; Sarah A Tishkoff; Beatrice H Hahn
Journal:  Int J Parasitol       Date:  2018-02-21       Impact factor: 3.981

Review 10.  Key Elements on the Pathway to HCV Elimination: Lessons Learned From the AASLD HCV Special Interest Group 2020.

Authors:  Jordan J Feld; John W Ward
Journal:  Hepatol Commun       Date:  2021-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.